By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Immunocore Limited 

90 Park Drive
Milton Park
Abingdon  Oxon  OX14 4RY  United Kingdom
Phone: 44-0-1235-438600 Fax: 44-0-1235-438601



Company News
Immunocore Presents Positive Monotherapy Data In Uveal Melanoma At The Society For Melanoma Research (SMR) 2016 Congress 11/9/2016 10:16:03 AM
Immunocore Ranked In The Sunday Times Hiscox Tech Track 100 9/12/2016 11:02:22 AM
Immunocore’s Immtav Shown To Redirect The Immune System To Kill HIV-Infected Cells From Patients Treated With Antiretroviral Therapy 6/8/2016 10:46:24 AM
ASCO2016: Immunocore Presents Positive Imcgp100 Phase I Data At The 2016 ASCO Annual Meeting 6/6/2016 11:52:21 AM
MediGene AG (MDGEF.PK) Sells Partial Stake In Immunocore 4/4/2016 11:44:27 AM
Immunocore's IMCgp100 Starts Phase I Trial For The Treatment Of Uveal Melanoma 3/30/2016 7:20:42 AM
Immunocore’s IMCgp100 Granted Orphan Drug Designation By U.S. FDA For The Treatment Of Uveal Melanoma 1/25/2016 11:22:50 AM
Immunocore Starts Clinical Trial With IMCgp100 In Combination With MedImmune (AZN) Immunotherapies Durvalumab And Tremelimumab 1/20/2016 6:02:01 AM
Immunocore And GlaxoSmithKline (GSK) Select First ImmTAC Clinical Candidate In Discovery Collaboration 1/6/2016 9:46:35 AM
Immunocore Raises $5 Million Series A Financing To Advance Novel Cancer Immunotherapies 12/21/2015 4:51:39 PM